糖尿病或代谢综合征人群结直肠癌筛查的风险适配起始年龄
基于GLOBOCAN 2022数据库,计算欧洲和北美30至50岁各年龄的5年结直肠癌累积风险,结合2020-2023年荟萃分析的风险估计,推导糖尿病或代谢综合征人群达到平均风险人群50岁或45岁时结直肠癌风险水平的年龄。糖尿病和代谢综合征人群比平均风险人群提前三至四年达到相应风险水平。
要点
- 糖尿病或代谢综合征人群比平均风险人群提前三至四年达到同等结直肠癌风险。
- 欧洲糖尿病者达平均风险50岁水平年龄为47岁(95%CI 45-49),北美为46岁(42-49)。
- 欧洲代谢综合征者达平均风险50岁水平年龄为47岁(47-48),北美为46岁(46-47)。
核心结论
- 糖尿病或代谢综合征人群比平均风险人群提前三至四年达到同等结直肠癌风险水平。
- 结果为定义这些高危人群的风险适配结直肠癌筛查起始年龄提供经验性指导。
研究设计与样本
- 基于GLOBOCAN 2022数据库,计算欧洲(总体及德国、法国、英国、意大利)和北美(美国和加拿大)30至50岁各年龄的5年结直肠癌累积风险。
- 利用2020-2023年荟萃分析的风险估计,推导糖尿病或代谢综合征人群达到平均风险人群50岁(aCR50)或45岁(aCR45)时结直肠癌风险水平的年龄。
主要发现
- 糖尿病者达aCR50年龄:欧洲47岁(95%CI 45-49),北美46岁(42-49)。
- 代谢综合征者达aCR50年龄:欧洲47岁(47-48),北美46岁(46-47)。
- 各国间差异极小,偏差不超过一年。
- 筛查项目从45岁开始时,糖尿病者达aCR45年龄:欧洲42岁(41-44),北美41岁(38-44)。
- 代谢综合征者达aCR45年龄:欧洲43岁(42-43),北美41岁(41-42)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with diabetes and metabolic syndrome have an increased risk of colorectal cancer (CRC), suggesting earlier screening than the average-risk population may be warranted. AIMS: To derive risk-adapted starting ages of CRC screening for people with diabetes or metabolic syndrome. METHODS: We determined 5-year cumulative risks of CRC at individual ages between 30 and 50 across Europe (overall and individually for Germany, France, the UK and Italy) and North America (the United States and Canada) based on the GLOBOCAN 2022 database. Using risk estimates from meta-analyses (2020-2023), we derived the ages at which individuals with diabetes or metabolic syndrome reach the same CRC risk as the average-risk population at age 50 (aCR50) or 45 (aCR45). RESULTS: Individuals with diabetes were estimated to reach aCR50 at age 47 (95% confidence interval, 45-49) in Europe and 46 (42-49) in North America. For metabolic syndrome, the corresponding ages were 47 (47-48) in Europe and 46 (46-47) in North America. Disparities across countries were minimal, with deviations of up to no more than one year. For screening programmes starting at age 45, corresponding risk-adapted starting ages for people with diabetes or metabolic syndrome were estimated to be 42 (41-44) and 43 (42-43) for Europe and 41 (38-44) and 41 (41-42) for North America, respectively. CONCLUSIONS: People with diabetes or metabolic syndrome reach risk levels comparable to the average risk population three to four years earlier. Our results offer empirical guidance for defining risk-adapted starting ages of CRC screening for these high-risk groups.
引用
- Seum T, Hoffmeister M, Brenner H, et al. Risk-Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome. Aliment Pharmacol Ther. 2024. PMID: 39686687. doi:10.1111/apt.18435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。